Justice Department Challenges WilmerHale’s Role in 23andMe Bankruptcy Over Conflict of Interest Concerns

The legal landscape surrounding 23andMe’s ongoing bankruptcy proceedings took a new turn as the U.S. Justice Department’s bankruptcy watchdog challenged the participation of law firm WilmerHale in assessing privacy matters related to the potential sale of the company’s genetic data. The Department of Justice has expressed concerns over potential conflicts of interest arising from WilmerHale’s dual role. The firm, while representing a law professor tasked with making important privacy-related recommendations, is simultaneously involved with Regeneron Pharmaceuticals Inc. on unrelated matters.

The core of the DOJ’s argument is centered on the risk of WilmerHale compromising their duty of loyalty. This concern stems from the notion that WilmerHale may inadvertently downplay critical privacy considerations concerning the sale of genetic data from 23andMe’s customers, given its obligations to its client Regeneron. According to the DOJ’s filing on the matter, the potential conflict of interest is significant enough to warrant the firm’s removal from these proceedings.

Complicating the scenario further is the outcome of a recent auction where Regeneron was edged out by a nonprofit organization overseen by 23andMe’s former CEO. Despite the auction results, the situation puts a spotlight on WilmerHale’s role and emphasizes the inherent complexities of managing fiduciary duties amidst overlapping professional engagements.

Legal experts within the industry will be closely monitoring the developments of this case, as it underscores the delicate balancing act firms face when grappling with multiple client commitments. The DOJ’s stance invites scrutiny and raises broader ethical questions regarding how law firms manage dual loyalties and potential conflicts.